Laura King
TACTILE SYSTEMS TECHNOLOGYAbout Laura G. King
Independent director at Tactile Systems Technology (TCMD) since January 13, 2025; age 61. Serves on the Audit Committee and the Compliance and Reimbursement Committee. Background: co‑founder and CEO of BiaCure, Inc. (since 2023); previously co‑founder and CEO of Elucent Medical (2014–2023) and CEO of NeuWave Medical (2007–2013); 22‑year career at GE, including Company Officer as CEO of GE Healthcare’s Global Interventional Business and earlier senior audit/finance roles (including CIO and CFO, Consumer and ECM Motors) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BiaCure, Inc. | Co‑founder & Chief Executive Officer | 2023–present | Early‑stage medical device leadership |
| Elucent Medical | Co‑founder & Chief Executive Officer | 2014–2023 | Product innovation and commercialization in med‑tech |
| NeuWave Medical | President & Chief Executive Officer | 2007–2013 | Growth leadership in medical devices |
| GE Healthcare – Global Interventional Business | President & Chief Executive Officer (Company Officer) | — (within a 22‑year GE career) | Led global interventional business; senior operating oversight |
| GE (Consumer and ECM Motors) | CIO; CFO | — (within a 22‑year GE career) | Senior audit/finance and systems leadership |
External Roles
| Organization | Type | Role | Notes |
|---|---|---|---|
| Sonoptima | Private company | Director | Medical device focus |
| Nextrast | Private company | Director | Medical device focus |
| BiaCure Therapies | Private company | Director | Medical device focus |
No other public company directorships disclosed for Ms. King .
Board Governance
- Independence: Board determined all directors except CEO Sheri Dodd and former CEO Daniel Reuvers are independent; Ms. King is independent .
- Current committee assignments: Audit Committee; Compliance & Reimbursement Committee .
- Committee oversight scope and recent activity:
- Audit: 7 meetings in 2024; responsibilities include auditor oversight, ICFR, legal/regulatory compliance, cybersecurity/IT/data security risk oversight .
- Compliance & Reimbursement: 4 meetings in 2024; oversees regulatory compliance and corporate responsibility/ESG matters .
- Audit Committee Report signatories include Ms. King, confirming current membership at time of the 2025 proxy .
- Board activity and attendance: Board held 6 meetings in 2024; each director then in office attended at least 75% of Board and committee meetings (Ms. King joined in 2025) .
- Election and shareholder support (2025 Annual Meeting):
- Votes for Ms. King: 15,862,873; Withheld: 130,435; Broker non‑votes: 3,037,240 .
- Say‑on‑pay (advisory): For 15,658,844; Against 321,637; Abstain 12,827; Broker non‑votes 3,037,240 (strong support) .
- 2025 Equity Incentive Plan: For 15,286,584; Against 697,589; Abstain 9,135; Broker non‑votes 3,037,240 .
Fixed Compensation
| Element | Amount/Terms |
|---|---|
| Annual Board cash retainer | $50,000 per non‑employee director |
| Additional Chair of the Board retainer | $50,000 (if applicable) |
| Committee retainers (Member/Chair) | Audit: $10,000/$20,000; Compensation: $7,500/$15,000; Nominating & Governance: $5,000/$10,000; Compliance & Reimbursement: $5,000/$10,000 |
| Cash in RSUs election | Directors may elect 10%–100% of cash retainers in RSUs; such RSUs are fully vested upon grant and settle upon separation or change in control |
2024 director compensation recipients and amounts are shown for then‑serving directors (Ms. King joined 2025) .
Performance Compensation
| Equity Type | Grant Practice | Vesting | 2024 Annual Grant Reference |
|---|---|---|---|
| RSUs (annual director award) | Approximately $145,000 value per non‑employee director (granted on 2024 Annual Meeting date) | Vest in full at earlier of one year from grant or next Annual Meeting, subject to service | 10,469 RSUs granted to each then‑serving non‑employee director on May 8, 2024 |
| Options | No regular option grants for directors in 2024 (aggregate outstanding options disclosed for certain directors; all exercisable) | — | — |
Performance metrics are not applied to non‑employee director pay at TCMD; director equity is time‑based RSUs (no TSR or financial targets) .
Other Directorships & Interlocks
| Company | Public/Private | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Sonoptima | Private | Director | No TCMD related‑party transactions disclosed since Jan 1, 2024 |
| Nextrast | Private | Director | No TCMD related‑party transactions disclosed since Jan 1, 2024 |
| BiaCure Therapies | Private | Director | No TCMD related‑party transactions disclosed since Jan 1, 2024 |
TCMD reports no related‑party transactions >$120,000 since Jan 1, 2024; policy requires Audit Committee approval for any such items .
Expertise & Qualifications
- Seasoned healthcare and medical device operator (multiple CEO roles; product innovation/commercialization focus) .
- Prior GE Company Officer with global P&L leadership (GE Healthcare Interventional) and senior audit/finance systems roles (CIO/CFO) .
- Committee fit: Audit (financial literacy requirement met at committee level; Audit Committee financial expert is Ms. Volkart), Compliance & Reimbursement (regulatory and ESG oversight) .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class | Notes |
|---|---|---|---|
| Laura G. King | 2,970 | <1% | Includes 2,970 RSUs scheduled to vest within 60 days after Mar 13, 2025 |
- Director Stock Ownership Guidelines: 5x annual Board cash retainer; directors must reach the level by the later of December 9, 2026 or 5 years after becoming subject; until met, must retain at least 50% of net profit shares from equity settlements .
- Hedging/Pledging: Directors are prohibited from pledging, hedging, short sales, and derivatives on TCMD stock (policy applies to directors and officers) .
Governance Assessment
- Strengths
- Independent director with deep med‑tech operating experience; current CEO of a healthcare venture and prior GE Healthcare Company Officer .
- Appointed to two high‑impact committees (Audit; Compliance & Reimbursement), aligning with financial, regulatory, and ESG oversight priorities; Audit Committee report bears her name .
- Strong initial shareholder support (votes FOR ~99.2% of votes cast excluding broker non‑votes) and robust say‑on‑pay approval, signaling investor confidence in governance and compensation practices .
- Solid guardrails: director ownership guidelines (5x retainer), clawback policies, prohibition on hedging/pledging, independent comp consultant, and no tax gross‑ups .
- No related‑party transactions involving Ms. King disclosed; Board committees fully independent; Board conducts annual evaluations and engaged third‑party assessments .
- Watch items
- Multiple external commitments (CEO at BiaCure; director at several private med‑tech firms) may require ongoing monitoring for time/attention capacity; the Nominating & Governance process explicitly considers ability to devote sufficient time .
- Director‑specific attendance for 2025 will be assessable in the next proxy; 2024 attendance data covers only directors then in office .
Appendix: 2025 Shareholder Vote Outcomes (Select Items)
| Item | For | Against | Abstain | Broker Non‑Votes |
|---|---|---|---|---|
| Election – Laura G. King | 15,862,873 | 130,435 | — | 3,037,240 |
| Say‑on‑Pay (Advisory) | 15,658,844 | 321,637 | 12,827 | 3,037,240 |
| 2025 Equity Incentive Plan | 15,286,584 | 697,589 | 9,135 | 3,037,240 |
Notes on Committee Activity (Reference)
| Committee | 2024 Meetings | Key Oversight Areas |
|---|---|---|
| Audit | 7 | Auditor oversight, ICFR, legal/regulatory, risk, cybersecurity/IT/data security, whistleblower procedures |
| Compliance & Reimbursement | 4 | Regulatory compliance; corporate responsibility including sustainability, social and public policy |
Ms. King joined the Board on January 13, 2025; 2024 meeting counts reflect committee activity before her appointment .